Inside the Clinic: Treating AYA ALL : Episode 4
Opinion
Video
AYA ALL: Role of Asparaginase Erwinia Chrysanthemi
Author(s):
Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.
EP: 1.Clinical Scenario: A 23-Year-Old Male with AYA ALL
EP: 2.AYA ALL: Overview and Risk Stratification
EP: 3.AYA ALL: Pediatric and Adult Inspired Regimens
Now Viewing
EP: 4.AYA ALL: Role of Asparaginase Erwinia Chrysanthemi
EP: 5.Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions
EP: 6.ALL AYA: Coordination of Care
EP: 7.Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL
EP: 8.CALBG 10403 in AYA ALL
EP: 9.The Potential of Modified Treatment Regimens in AYA ALL
EP: 10.The Future of AYA ALL
Video content above is prompted by the following questions:
- Please comment on the trial led to the approval of use for asparaginase erwinia chrysanthemi in AYA ALL.
- How does for asparaginase erwinia chrysanthemi work?
- What are your thoughts on the key efficacy outcomes?
Related Videos
Related Content
